NASDAQ:KITE - Kite Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$179.79 0.00 (0.00 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$179.79
Today's Range$179.79 - $179.79
52-Week Range$39.82 - $179.99
VolumeN/A
Average Volume1.65 million shs
Market Capitalization$10.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01
Quick Ratio9.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,092.54%
Return on Equity-59.15%
Return on Assets-48.12%

Miscellaneous

Employees447
Outstanding Shares57,370,000

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) issued its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $5.74 million. Kite Pharma had a negative return on equity of 59.15% and a negative net margin of 1,092.54%. The firm's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.54) EPS. View Kite Pharma's Earnings History.

What price target have analysts set for KITE?

10 Wall Street analysts have issued twelve-month price targets for Kite Pharma's shares. Their predictions range from $74.00 to $135.00. On average, they anticipate Kite Pharma's stock price to reach $106.3333 in the next twelve months. View Analyst Ratings for Kite Pharma.

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

Has Kite Pharma been receiving favorable news coverage?

News articles about KITE stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Kite Pharma?

Shares of KITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

How big of a company is Kite Pharma?

Kite Pharma has a market capitalization of $10.28 billion. Kite Pharma employs 447 workers across the globe.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (KITE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  643 (Vote Outperform)
Underperform Votes:  304 (Vote Underperform)
Total Votes:  947
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.